Dyne Therapeutics · 1 day ago
Director, Imaging Biomarkers
Waltham, MA
Full-time
Onsite
Director/Executive
$196K/yr - $240K/yr
10+ years expDyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The Director of Imaging Biomarkers leads the development and execution of innovative imaging strategies across Dyne’s therapeutic programs, ensuring scientific rigor and clinical relevance in imaging biomarker strategies to support therapeutic development.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Collaborate with cross-functional teams including clinical development, biostatistics, and regulatory affairs to ensure that imaging biomarkers are effectively integrated into clinical trial protocols
Enable the delivery of high-quality data supporting both internal decision making and external communications with stakeholders, including regulatory authorities
Define and execute the imaging biomarker strategy aligned with clinical and translational objectives
Serve as the subject matter expert for imaging biomarkers across pre-clinical and clinical programs
Lead the development, validation, and qualification of imaging biomarkers for disease characterization, patient stratification, and pharmacodynamic assessment
Partner with Clinical Development, Translational Biomarkers, Biostatistics, Data Management and Regulatory teams to integrate imaging biomarkers into Dyne clinical trials
Evaluate and implement cutting-edge imaging technologies (e.g., MRI, PET, CT, ultrasound, optical imaging)
Ensure compliance with regulatory standards for imaging biomarker development and qualification
Collaborate with external imaging CROs, academic institutions, and technology vendors to deploy imaging biomarkers into Dyne clinical trials
Oversee vendor selection and budget management for imaging-related activities
Manage imaging biomarker operations in clinical studies including protocol development, support site training, and data quality assurance
Foster a culture of innovation and scientific rigor
Qualification
Required
Ph.D., M.D., or equivalent in Biomedical Engineering, Medical Physics, Radiology, or related scientific disciplines
10+ years of experience in imaging biomarker development within pharma, biotech, or academic research
Blend of technical knowledge, scientific acumen, and strategic vision to foster collaborations with academic institutions, industry partners, and clinical experts
Deep scientific expertise in at least one major imaging modality (preferably MRI) and a strong understanding of image acquisition, processing, and analysis
Proven track record in applying imaging biomarkers in clinical trials and regulatory submissions
Expertise in quantitative imaging methodologies, image analysis software, and imaging data interpretation
Strong leadership and project management skills with ability to influence across functions
Excellent communication and presentation skills
Preferred
Familiarity with AI/ML approaches for image analysis to improve efficiency, accuracy, and uncover complex patterns in imaging data
Understanding and implementation of digital biomarkers using wearables, sensors, or other digital health technologies
Knowledge of disease-specific imaging biomarkers (e.g., neurology, cardiology or neuromuscular)
Company
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
51-200 employees
H1B Sponsorship
Dyne Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (6)
2024 (7)
2023 (1)
2022 (3)
2021 (6)
Funding
Current Stage
Public CompanyTotal Funding
$1.67BKey Investors
Hercules CapitalAtlas Venture
2025-12-09Post Ipo Equity· $402.5M
2025-06-30Post Ipo Equity· $230M
2025-06-30Post Ipo Debt· $100M
Leadership Team
John Cox
Chief Executive Officer
Recent News
2026-01-11
2026-01-07
Company data provided by crunchbase